Cholinergic Pathology in Dementia with Lewy Bodies

  • John-Paul Taylor
  • Daniel Collerton
  • Fiona LeBeau
  • Elaine Perry
Chapter

Abstract

Cholinergic dysfunction is a major feature of dementia with Lewy bodies (DLB) and makes a significant contribution to the cognitive impairment and other challenging symptoms seen in this condition. Despite this, or indeed, because of this, manipulation of the cholinergic system can offer significant therapeutic opportunities for treating DLB, and this is reflected in the fact that cholinesterase inhibitors remain one of our best treatments in this condition. In this chapter, we will explore the pathology of cholinergic dysfunction in DLB, review findings from both post-mortem and imaging studies and place this within a clinical framework.

Keywords

Cholinergic Dementia with Lewy bodies Acetylcholine 

References

  1. 1.
    Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40. doi:10.1016/s0140-6736(13)62106-6.CrossRefPubMedGoogle Scholar
  2. 2.
    Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep. 2012;12(5):492–501. doi:10.1007/s11910-012-0290-7.CrossRefPubMedGoogle Scholar
  3. 3.
    Candy JM, Perry RH, Perry EK, et al. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci. 1983;59(2):277–89.CrossRefPubMedGoogle Scholar
  4. 4.
    Perry RH, Tomlinson BE, Candy JM, et al. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet. 1983;2(8353):789–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res. 2011;221(2):564–73. doi:10.1016/j.bbr.2009.12.048.CrossRefPubMedGoogle Scholar
  6. 6.
    Hall H, Reyes S, Landeck N, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014;137(Pt 9):2493–508. doi:10.1093/brain/awu193.CrossRefPubMedGoogle Scholar
  7. 7.
    Liu AK, Chang RC, Pearce RK, et al. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer’s and Parkinson’s disease. Acta Neuropathol. 2015;129(4):527–40. doi:10.1007/s00401-015-1392-5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chui HC, Mortimer JA, Slager U, et al. Pathologic correlates of dementia in Parkinson’s disease. Arch Neurol. 1986;43(10):991–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1985;48(5):413–21.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Alexandris A, Liu AK, Chang RC, et al. Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders. Acta Neuropathol Commun. 2015;3:77. doi:10.1186/s40478-015-0249-4.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer’s and Parkinson’s disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol. 1988;273(4):543–57. doi:10.1002/cne.902730409.CrossRefPubMedGoogle Scholar
  12. 12.
    Cullen KM, Halliday GM. Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology. Neurobiol Aging. 1998;19(4):297–306.CrossRefPubMedGoogle Scholar
  13. 13.
    Mattila PM, Roytta M, Lonnberg P, et al. Choline acetytransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol (Berl). 2001;102(2):160–6.Google Scholar
  14. 14.
    Piggott MA, Owens J, O’Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease. J Chem Neuroanat. 2003;25(3):161–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience. 1995;64(2):385–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Court J, Spurden D, Lloyd S, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 1999;73(4):1590–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Sahin HA, Emre M, Ziabreva I, et al. The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol. 2006;111(2):115–25. doi:10.1007/s00401-005-0003-2.CrossRefPubMedGoogle Scholar
  18. 18.
    Kalaitzakis ME, Walls AJ, Pearce RK, et al. Striatal Abeta peptide deposition mirrors dementia and differentiates DLB and PDD from other Parkinsonian syndromes. Neurobiol Dis. 2011;41(2):377–84. doi:10.1016/j.nbd.2010.10.005.CrossRefPubMedGoogle Scholar
  19. 19.
    Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience. 2000;98(1):79–87.CrossRefPubMedGoogle Scholar
  20. 20.
    Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology. 2004;29(1):108–16.CrossRefPubMedGoogle Scholar
  21. 21.
    Ray M, Bohr I, McIntosh JM, et al. Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. Neurosci Lett. 2004;372(3):220–5. doi:10.1016/j.neulet.2004.09.042.CrossRefPubMedGoogle Scholar
  22. 22.
    Bohr IJ, Ray MA, McIntosh JM, et al. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus. Exp Neurol. 2005;191(2):292–300. doi:10.1016/j.expneurol.2004.10.004.CrossRefPubMedGoogle Scholar
  23. 23.
    Gotti C, Moretti M, Bohr I, et al. Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis. 2006;23(2):481–9. doi:10.1016/j.nbd.2006.04.005.CrossRefPubMedGoogle Scholar
  24. 24.
    Lee JE, Cho KH, Song SK, et al. Exploratory analysis of neuropsychological and neuroanatomical correlates of progressive mild cognitive impairment in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(1):7–16. doi:10.1136/jnnp-2013-305062.CrossRefPubMedGoogle Scholar
  25. 25.
    Delli Pizzi S, Maruotti V, Taylor JP, et al. Relevance of subcortical visual pathways disruption to visual symptoms in dementia with Lewy bodies. Cortex. 2014;59:12–21. doi:10.1016/j.cortex.2014.07.003.CrossRefPubMedGoogle Scholar
  26. 26.
    Delli Pizzi S, Franciotti R, Taylor JP, et al. Thalamic involvement in fluctuating cognition in Dementia with Lewy Bodies: magnetic resonance evidences. Cerebral Cortex (New York: 1991). 2015;25(10):3682–9. doi:10.1093/cercor/bhu220.Google Scholar
  27. 27.
    Ziabreva I, Ballard CG, Aarsland D, et al. Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. Neurobiol Aging. 2006;27(3):433–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Kotagal V, Muller ML, Kaufer DI, et al. Thalamic cholinergic innervation is spared in Alzheimer disease compared to Parkinsonian disorders. Neurosci Lett. 2012;514(2):169–72. doi:10.1016/j.neulet.2012.02.083.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Seidel K, Mahlke J, Siswanto S, et al. The brainstem pathologies of Parkinson’s disease and dementia with Lewy bodies. Brain Pathol. 2015;25(2):121–35. doi:10.1111/bpa.12168.CrossRefPubMedGoogle Scholar
  30. 30.
    Schmeichel AM, Buchhalter LC, Low PA, et al. Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology. 2008;70(5):368–73. doi:10.1212/01.wnl.0000298691.71637.96.CrossRefPubMedGoogle Scholar
  31. 31.
    Dugger BN, Murray ME, Boeve BF, et al. Neuropathological analysis of brainstem cholinergic and catecholaminergic nuclei in relation to rapid eye movement (REM) sleep behaviour disorder. Neuropathol Appl Neurobiol. 2012;38(2):142–52. doi:10.1111/j.1365-2990.2011.01203.x.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Pahapill PA, Lozano AM. The pedunculopontine nucleus and Parkinson’s disease. Brain. 2000;123(Pt 9):1767–83.CrossRefPubMedGoogle Scholar
  33. 33.
    Janzen J, van ‘t Ent D, Lemstra AW, et al. The pedunculopontine nucleus is related to visual hallucinations in Parkinson’s disease: preliminary results of a voxel-based morphometry study. J Neurol. 2012;259(1):147–54. doi:10.1007/s00415-011-6149-z.CrossRefPubMedGoogle Scholar
  34. 34.
    Park HE, Park IS, Oh YS, et al. Subcortical whiter matter hyperintensities within the cholinergic pathways of patients with dementia and parkinsonism. J Neurol Sci. 2015;353(1–2):44–8. doi:10.1016/j.jns.2015.03.046.CrossRefPubMedGoogle Scholar
  35. 35.
    Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol. 1996;40(3):399–410.CrossRefPubMedGoogle Scholar
  36. 36.
    Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65(11):1716–22. doi:10.1212/01.wnl.0000191154.78131.f6.CrossRefPubMedGoogle Scholar
  37. 37.
    Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73(4):273–8. doi:10.1212/WNL.0b013e3181ab2b58.CrossRefPubMedGoogle Scholar
  38. 38.
    Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885–92. doi:10.1212/WNL.0b013e3181d55f61.CrossRefPubMedGoogle Scholar
  39. 39.
    Marcone A, Garibotto V, Moresco RM, et al. [11C]-MP4A PET cholinergic measurements in amnestic mild cognitive impairment, probable Alzheimer’s disease, and dementia with Lewy bodies: a Bayesian method and voxel-based analysis. J Alzheimers Dis. 2012;31(2):387–99. doi:10.3233/JAD-2012-111748.PubMedGoogle Scholar
  40. 40.
    O’Brien JT, Colloby SJ, Pakrasi S, et al. Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage. 2008;40(3):1056–63. doi:10.1016/j.neuroimage.2008.01.010.CrossRefPubMedGoogle Scholar
  41. 41.
    Colloby SJ, Perry EK, Pakrasi S, et al. Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer’s disease and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2010;18(1):86–90. doi:10.1097/JGP.0b013e3181b972aa.CrossRefPubMedGoogle Scholar
  42. 42.
    Isaias IU, Spiegel J, Brumberg J, et al. Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson’s disease. Front Aging Neurosci. 2014;6:213. doi:10.3389/fnagi.2014.00213.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Colloby SJ, Pakrasi S, Firbank MJ, et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson’s disease dementia. NeuroImage. 2006;33(2):423–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Colloby S, McKeith I, Burn D, et al. Cholinergic and perfusion brain networks in Parkinson’s disease dementia. Neurology. 2016; pii: 10.1212/WNL.0000000000002839. [Epub ahead of print]
  45. 45.
    Kim HJ, Lee JE, Shin SJ, et al. Analysis of the substantia innominata volume in patients with Parkinson’s disease with dementia, dementia with Lewy bodies, and Alzheimer’s disease. J Mov Disord. 2011;4(2):68–72. doi:10.14802/jmd.11014.Google Scholar
  46. 46.
    Grothe MJ, Schuster C, Bauer F, et al. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia. J Neurol. 2014;261(10):1939–48. doi:10.1007/s00415-014-7439-z.CrossRefPubMedGoogle Scholar
  47. 47.
    Colloby SJ, Elder GJ, Rabee R, et al. Structural grey matter changes in the substantia innominata in Alzheimer’s disease and dementia with Lewy bodies: a DARTEL-VBM study. Int J Geriatr Psychiatry. 2016. doi:10.1002/gps.4500.Google Scholar
  48. 48.
    Satoh M, Ishikawa H, Meguro K, et al. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: the Osaki-Tajiri project. Eur Neurol. 2010;64(6):337–44. doi:10.1159/000322121.CrossRefPubMedGoogle Scholar
  49. 49.
    Fong T, Inouye S, Dai W, et al. Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? Brain Imag Behavior. 2010;5(1):25–35. doi:10.1007/s11682-010-9108-x.CrossRefGoogle Scholar
  50. 50.
    Gratwicke J, Kahan J, Zrinzo L, et al. The nucleus basalis of Meynert: a new target for deep brain stimulation in dementia? Neurosci Biobehav Rev. 2013;37(10 Pt 2):2676–88. doi:10.1016/j.neubiorev.2013.09.003.CrossRefPubMedGoogle Scholar
  51. 51.
    Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138(Pt 6):1454–76. doi:10.1093/brain/awv104.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Collerton D, Burn D, McKeith I, et al. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord. 2003;16(4):229–37.CrossRefPubMedGoogle Scholar
  53. 53.
    Hanyu H, Asano T, Sakurai H, et al. MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia. AJNR Am J Neuroradiol. 2002;23(1):27–32.PubMedGoogle Scholar
  54. 54.
    Choi SH, Jung TM, Lee JE, et al. Volumetric analysis of the substantia innominata in patients with Parkinson’s disease according to cognitive status. Neurobiol Aging. 2012;33(7):1265–72. doi:10.1016/j.neurobiolaging.2010.11.015.CrossRefPubMedGoogle Scholar
  55. 55.
    Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol. 2006;253(2):242–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Lorenz R, Samnick S, Dillmann U, et al. Nicotinic alpha4beta2 acetylcholine receptors and cognitive function in Parkinson’s disease. Acta Neurol Scand. 2014;130(3):164–71. doi:10.1111/ane.12259.CrossRefPubMedGoogle Scholar
  57. 57.
    Kenny ER, Blamire AM, Firbank MJ, et al. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer’s disease. Brain. 2012;135(Pt 2):569–81. doi:10.1093/brain/awr327.CrossRefPubMedGoogle Scholar
  58. 58.
    Peraza LR, Kaiser M, Firbank M, et al. fMRI resting state networks and their association with cognitive fluctuations in dementia with Lewy bodies. NeuroImage Clinical. 2014;4:558–65. doi:10.1016/j.nicl.2014.03.013.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Peraza LR, Taylor JP, Kaiser M. Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging. 2015;36(9):2458–67. doi:10.1016/j.neurobiolaging.2015.05.015.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Dauwan M, van Dellen E, van Boxtel L, et al. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer’s disease and controls. Neurobiol Aging. 2016;41:122–9. doi:10.1016/j.neurobiolaging.2016.02.017.CrossRefPubMedGoogle Scholar
  61. 61.
    McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology. 2005;65:1863–72.CrossRefPubMedGoogle Scholar
  62. 62.
    Ballard C, Aarsland D, Francis P, et al. Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. Drugs Aging. 2013;30(8):603–11. doi:10.1007/s40266-013-0092-x.CrossRefPubMedGoogle Scholar
  63. 63.
    Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol. 2000;48(6):868–76.CrossRefPubMedGoogle Scholar
  64. 64.
    Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav. 2001;70(4):571–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Teaktong T, Piggott MA, McKeith IG, et al. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res. 2005;161(2):299–305.CrossRefPubMedGoogle Scholar
  66. 66.
    Marra C, Quaranta D, Profice P, et al. Central cholinergic dysfunction measured “in vivo” correlates with different behavioral disorders in Alzheimer’s disease and dementia with Lewy body. Brain Stimul. 2012;5(4):533–8. doi:10.1016/j.brs.2011.08.009.CrossRefPubMedGoogle Scholar
  67. 67.
    O’Brien JT, Colloby SJ, Pakrasi S, et al. Nicotinic [alpha]4[beta]2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. NeuroImage. 2008;40(3):1056–63.CrossRefPubMedGoogle Scholar
  68. 68.
    Hepp DH, Ruiter AM, Galis Y, et al. Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol. 2013;72(12):1162–70.Google Scholar
  69. 69.
    Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson’s disease. Mov Disord. 2011;26(14):2496–503. doi:10.1002/mds.23932.CrossRefPubMedGoogle Scholar
  70. 70.
    Onofrj M, Taylor JP, Monaco D, et al. Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behav Neurol. 2013;27(4):479–93. doi:10.3233/BEN-129022.CrossRefPubMedGoogle Scholar
  71. 71.
    Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci. 2005;28(6):737–57.PubMedGoogle Scholar
  72. 72.
    Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: A systematic review and meta-analysis. Am J Psychiatry. 2015:appiajp201514121582. doi:10.1176/appi.ajp.2015.14121582.
  73. 73.
    Ballard CG, Court JA, Piggott M, et al. Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. Conscious Cogn. 2002;11(3):461–74.CrossRefPubMedGoogle Scholar
  74. 74.
    Pimlott SL, Piggott M, Ballard C, et al. Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. Neurobiol Dis. 2006;1:50–6.CrossRefGoogle Scholar
  75. 75.
    Bonanni L, Thomas A, Tiraboschi P, et al. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(3):690–705. doi:10.1093/brain/awm322.CrossRefPubMedGoogle Scholar
  76. 76.
    Walker MP, Ayre GA, Cummings JL, et al. The clinician assessment of fluctuation and the one day fluctuation assessment scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry. 2000;177:252–6.CrossRefPubMedGoogle Scholar
  77. 77.
    Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology. 2000;54(8):1616–25.CrossRefPubMedGoogle Scholar
  78. 78.
    Gore RL, Vardy ER, O’Brien JT. Delirium and dementia with Lewy bodies: distinct diagnoses or part of the same spectrum? J Neurol Neurosurg Psychiatry. 2015;86(1):50–9. doi:10.1136/jnnp-2013-306389.CrossRefPubMedGoogle Scholar
  79. 79.
    Taylor JP, Colloby SJ, McKeith IG, et al. Covariant perfusion patterns provide clues to the origin of cognitive fluctuations and attentional dysfunction in dementia with Lewy bodies. Int Psychogeriatrics/IPA. 2013;25(12):1917–28. doi:10.1017/S1041610213001488.CrossRefGoogle Scholar
  80. 80.
    Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 2013;81(18):1611–6. doi:10.1212/WNL.0b013e3182a9f558.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Sarter M, Albin RL, Kucinski A, et al. Where attention falls: increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Exp Neurol. 2014;257:120–9. doi:10.1016/j.expneurol.2014.04.032.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 2009;73(20):1670–6. doi:10.1212/WNL.0b013e3181c1ded6.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Weathers SP, Kotagal V, Bohnen NI, et al. Risky driving and pedunculopontine nucleus-thalamic cholinergic denervation in Parkinson disease. Parkinsonism Relat Disord. 2014;20(1):13–6. doi:10.1016/j.parkreldis.2013.08.021.CrossRefPubMedGoogle Scholar
  84. 84.
    Rochester L, Yarnall AJ, Baker MR, et al. Cholinergic dysfunction contributes to gait disturbance in early Parkinson’s disease. Brain. 2012;135(Pt 9):2779–88. doi:10.1093/brain/aws207.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133(Pt 6):1747–54. doi:10.1093/brain/awq079.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015;138(Pt 3):653–63. doi:10.1093/brain/awu369.CrossRefPubMedGoogle Scholar
  87. 87.
    Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport. 1994;5(7):747–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Graff-Radford J, Boeve BF, Pedraza O, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain. 2012;135(Pt 8):2470–7. doi:10.1093/brain/aws173.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Fong TG, Inouye SK, Dai W, et al. Association cortex hypoperfusion in mild dementia with Lewy bodies: a potential indicator of cholinergic dysfunction? Brain Imaging Behav. 2011;5(1):25–35. doi:10.1007/s11682-010-9108-x.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  • John-Paul Taylor
    • 1
  • Daniel Collerton
    • 1
  • Fiona LeBeau
    • 1
  • Elaine Perry
    • 1
  1. 1.Institute of NeuroscienceNewcastle UniversityNewcastle upon TyneUK

Personalised recommendations